Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRM Mirum Pharmaceuticals, Inc.

Trading 12-22 11:29:10 EST

80.81

+3.07

+3.95%

High81.04	Low75.13	Vol302.52K
Open76.79	D1 Closing77.74	Amplitude7.60%
Mkt Cap4.18B	Tradable Cap3.23B	Total Shares51.68M
T/O23.99M	T/O Rate0.76%	Tradable Shares39.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":80.81,"timestamp":1766420947136,"preClose":77.74,"halted":0,"volume":302522,"delay":0,"floatShares":39985740,"shares":51683837,"eps":-0.83931,"marketStatus":"Trading","change":3.07,"latestTime":"12-22 11:29:10 EST","open":76.79,"high":81.04,"low":75.13,"amount":23991555.61352,"amplitude":0.076023,"askPrice":80.9,"askSize":40,"bidPrice":80.79,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-0.83931,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":77.74,"preHourTrading":{"tag":"盘前","latestPrice":76.88,"preClose":77.74,"latestTime":"09:28 EST","volume":766,"amount":59273.034040000006,"timestamp":1766413680084},"postHourTrading":{"tag":"盘后","latestPrice":77,"preClose":77.74,"latestTime":"19:12 EST","volume":180028,"amount":13995277.4957,"timestamp":1766189577414},"volumeRatio":0.691497,"impliedVol":0.3895,"impliedVolPercentile":0.332},"requestUrl":"/m/hq/s/MIRM/wiki","defaultTab":"wiki","newsList":[{"id":"2592190891","title":"Mirum Pharmaceuticals Inc - Files Patent Infringement Suits Against Anda Filers - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190891?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:23","pubTimestamp":1766179438,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2592197085","title":"Director Saira Ramasastry Sells Common Shares of Mirum Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197085","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197085?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:16","pubTimestamp":1766178985,"startTime":"0","endTime":"0","summary":"Saira Ramasastry, Director at Mirum Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9CV75Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Saira Ramasastry Sells Common Shares of Mirum Pharmaceuticals Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2592197449","title":"Mirum Pharmaceuticals Sues Generic Drugmakers Over Livmarli Patent Infringement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197449","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197449?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:07","pubTimestamp":1766178428,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Inc. has filed patent infringement lawsuits against Sandoz, Annora Pharma Private Limited, Zydus Lifesciences Global FZE, and Zenara Pharma Private Limited in the United States District Court for the District of Delaware. The company alleges that the filing of Abbreviated New Drug Applications  by these firms for generic versions of Livmarli infringes on Mirum’s Orange Book listed patents. As a result of the litigation, a 30-month stay has been imposed, preventing the FDA from granting final approval of the generic ANDAs before the expiration of the asserted patents.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL8HKmMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2592160257","title":"Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160257","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160257?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:09","pubTimestamp":1766153356,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals  said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay Therapeutics.The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","MIRM","BK4139","EQR","BK4215"],"gpt_icon":0},{"id":"2592579160","title":"BRIEF-Mirum Pharmaceuticals Announces Additional Private Placement Financing With Tcgx","url":"https://stock-news.laohu8.com/highlight/detail?id=2592579160","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592579160?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:07","pubTimestamp":1766153277,"startTime":"0","endTime":"0","summary":"BRIEF-Mirum Pharmaceuticals Announces Additional Private Placement Financing With TcgxDec 19 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS ANNOUNCES ADDITIONAL PRIVATE PLACEMENT F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA4MR8QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2592167495","title":"Mirum Pharmaceuticals Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2592167495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592167495?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:41","pubTimestamp":1766151660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2025 08:41 ET (13:41 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2592673951","title":"Mirum Pharmaceuticals Inc - Private Placement of 1 Mln of Commons Tock at $68.48 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2592673951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592673951?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:30","pubTimestamp":1766151000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA4MR8QP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2590519305","title":"Mirum Pharmaceuticals Grants Stock Options and RSUs to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2590519305","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590519305?lang=en_us&edition=fundamental","pubTime":"2025-12-11 08:00","pubTimestamp":1765411213,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Inc. has granted inducement awards to eight new employees as part of its 2020 Inducement Plan. The awards include non-qualified stock options to purchase 15,820 shares of common stock at an exercise price of $64.67 per share, vesting over four years with 25% vesting after one year and the remainder vesting monthly over the following 36 months. Additionally, 7,840 restricted stock units  have been granted, vesting in equal thirds over three years on each anniversary of the vesting commencement date. These awards are subject to continued service and the terms of the company's 2020 Inducement Plan and applicable award agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8HNVfY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2590609551","title":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590609551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590609551?lang=en_us&edition=fundamental","pubTime":"2025-12-11 08:00","pubTimestamp":1765411200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA5W06DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2590646321","title":"Sector Update: Health Care Stocks Softer Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2590646321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590646321?lang=en_us&edition=fundamental","pubTime":"2025-12-10 04:59","pubTimestamp":1765313988,"startTime":"0","endTime":"0","summary":"Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF  decreasing 1%.The iShares Biotechnology ETF  fell 1.7%.In corporate news, Mirum Pharmaceuticals'  acquisition of Bluejay Therapeutics expands its rare liver disease pipeline with brelovitug, a hepatitis delta virus therapy that has shown \"solid\" phase 2 results, Morgan Stanley said in a note Tuesday. Morgan Stanley kept its overweight rating and raised its price target to $95 from $81. Mirum shares were down 3.7%.Pfizer  said that it has signed an exclusive global collaboration and licensing deal with YaoPharma, a unit of Shanghai Fosun Pharmaceutical, to develop, make and commercialize YP05002 for chronic weight management. Pfizer shares were down 1.7%.CVS Health  lifted its full-year outlook on Tuesday amid ongoing efforts to strengthen its core businesses, while the healthcare company said it expects earnings in 2026 to be higher than","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0058720904.USD","BK4581","LU0211331839.USD","LU0225771236.USD","LU1732799900.SGD","IE00BBT3K403.USD","LU1983299246.USD","LU2347655156.SGD","LU0158827948.USD","BK4550","LU2133065610.SGD","LU0098860793.USD","SGXZ57979304.SGD","LU0912757837.SGD","LU2357305700.SGD","LU2111349929.HKD","LU0070302665.USD","BK4533","CVS","LU1162221912.USD","IE0002270589.USD","LU0795875086.SGD","LU1791710400.SGD","LU0162691827.USD","SG9999001176.USD","LU0106261372.USD","LU0971096721.USD","LU0320765489.SGD","LU0306807586.USD","BK4568","IE00B19Z3B42.SGD","SG9999003800.SGD","LU1548497426.USD","LU2028103732.USD","SG9999002232.USD","MIRM","IE00B19Z3581.USD","LU0106831901.USD","BK7095","TFX","BK4082","BK4585","LU0006061336.USD","SG9999002224.SGD","LU0306806265.USD","LU0225283273.USD","LABU","BK4139","BK4504","IE00BZ1G4Q59.USD","LU0170899867.USD","LU2271345857.HKD","LU0321505439.SGD","IE00B7SZLL34.SGD","BK4127","LU0314104364.USD","LU1883839398.USD","BK4196","SG9999001176.SGD","LU1894683264.USD","LU0557290698.USD","LU1059921491.USD","SG9999011175.SGD","LU0061475181.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1699723380.USD","LU0882574139.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU0072461881.USD","LU0158827781.USD","XBI","LU0528227936.USD","BK4592","LU1244550221.USD","BK4516","IE00BKVL7J92.USD","LU0225284248.USD","LU1989772840.SGD","LU0208291251.USD","LU2089284900.SGD","LU1989772923.USD","LU0320765646.SGD","LU1363072403.SGD","BK4599","IE00BLSP4239.USD","LU0267386448.USD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","LU1066051498.USD","LU1066053197.SGD","SG9999013999.USD","LU1732800096.USD","LU1791710582.SGD","LU1571399168.USD","LU0006306889.USD","LU0321505868.SGD","LU2023251221.USD","LU1074936037.SGD","LU1894683348.USD","LU1244550494.USD","LU0289739699.SGD","LU1244550577.SGD","LU0122379950.USD","XLV","LU2089283258.USD","LU0234570918.USD","BK4007","BK4588","BK4534","IE00BSNM7G36.USD","LU1057294990.SGD","LU0432979614.USD","LU0795875169.SGD","LU1720051108.HKD","LU1720051017.SGD","LU1668664300.SGD"],"gpt_icon":1},{"id":"2590034323","title":"Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2590034323","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590034323?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:27","pubTimestamp":1765301220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 12:27 ET (17:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2590323385","title":"Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323385","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323385?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:58","pubTimestamp":1765299485,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals' (MIRM) acquisition of Bluejay Therapeutics expands the company's rare liver disease pipeline with brelovitug, a hepatitis delta virus therapy that has shown \"solid\" phase 2 resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0795875086.SGD","LU1548497426.USD","LU1720051108.HKD","BK4139","LU1244550221.USD","LU2357305700.SGD","LU2271345857.HKD","LU1989772840.SGD","LU2111349929.HKD","MIRM","BK4534","LU0006306889.USD","LU0098860793.USD","LU0158827781.USD","LU1162221912.USD","LU0314104364.USD","LU2028103732.USD","BK4585","LU2023251221.USD","LU2347655156.SGD","LU1668664300.SGD","BK4588","LU0882574139.USD","IE00BKVL7J92.USD","LU1989772923.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU2089283258.USD","BK4127","LU0234570918.USD","LU0267386448.USD","LU0971096721.USD","LU0795875169.SGD","LU1720051017.SGD","LU0528227936.USD","BK4516","LU0158827948.USD","LU2089284900.SGD","LU0106831901.USD","LU1732800096.USD","LU0225283273.USD","LU0557290698.USD","LU1074936037.SGD","LU0106261372.USD","LU1363072403.SGD","LU1732799900.SGD","LU2133065610.SGD","BK4504","LU1244550577.SGD"],"gpt_icon":0},{"id":"2590434057","title":"Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2590434057","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590434057?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:39","pubTimestamp":1765294740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 10:39 ET (15:39 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2590534377","title":"Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534377","media":"MT Newswires Live","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534377?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:05","pubTimestamp":1765281910,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals (MIRM) has an average rating of buy and mean price target of $95.63, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2589435439","title":"Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589435439","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589435439?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:23","pubTimestamp":1765207435,"startTime":"0","endTime":"0","summary":"UPDATE 1-Mirum to buy Bluejay for up to $820 million in bet on liver-disease drugAdds analyst comment in paragraph 3, details from call in paragraph 5By Kamal  ChoudhuryDec 8 (Reuters) - Mirum Pharmac","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE158:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2589735688","title":"Mirum Pharma Exec Says No Change to 2025 Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735688?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:40","pubTimestamp":1765201256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0VH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2589554123","title":"Mirum Pharma CEO Says Addition of Brelovitug to Pipeline Will Bring Revenue Potential of Rare Disease Portfolio to Over $4 Bln - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2589554123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589554123?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:40","pubTimestamp":1765201256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2589356835","title":"Mirum Pharma Exec Says Co Expects to Return to Cash Flow Positive in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356835?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:40","pubTimestamp":1765201256,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0VH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2589355722","title":"Mirum Pharma Exec Expects Brelovitug Global Sales Potential of at Least $750 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355722?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:40","pubTimestamp":1765201256,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0VH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2589355362","title":"BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355362","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355362?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198807,"startTime":"0","endTime":"0","summary":"BRIEF-Mirum Pharmaceuticals Enters Into Definitive Agreement To Acquire Bluejay TherapeuticsDec 8  - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS: DEAL APPROVED BY BOARDS OF BOTH COS AND EXPECTED TO CLOSE IN Q1 2026MIRUM PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE BLUEJAY THERAPEUTICSMIRUM PHARMACEUTICALS: ENTERED INTO DEFINITIVE AGREEMENT WITH SYNDICATE OF HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENTMIRUM PHARMACEUTICALS: TO BUY BLUEJAY FOR $250 MILLION IN CASH, $370 MILLION IN CO'S COMMON STOCK & SALES-BASED MILESTONE PAYMENTS OF UPTO $200 MILLION IN CASHMIRUM PHARMACEUTICALS: AZURE PHASE 3 PROGRAM CURRENTLY ENROLLING PATIENTS, WITH TOP-LINE DATA EXPECTED IN 2H 2026 WITH BLA SUBMISSION, LAUNCH IN 2027MIRUM PHARMACEUTICALS: PRIVATE PLACEMENT EXPECTED TO CLOSE CONCURRENTLY WITH ACQUISITION & RESULT IN GROSS PROCEEDS TO CO OF ABOUT $200 MILLIONMIRUM PHARMACEUTICALS: BRELOVITUG BEING EVALUATED IN AZURE PHASE 3 REGISTRATIONAL PROGRAM FOR HDVFurther company covera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3W4067:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":0.196},{"period":"1month","weight":0.1037},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.5443},{"period":"1year","weight":0.8901},{"period":"ytd","weight":0.88}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.026003},{"month":2,"riseRate":0.833333,"avgChangeRate":0.061659},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.05038},{"month":4,"riseRate":0.5,"avgChangeRate":0.059141},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.035958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.313024}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}